Has Honey East, MD received payments from drug or device companies?

Yes. Drug and device makers reported $903,720 in general payments to Honey East, MD across 1,956 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Honey East, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Honey East, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Honey East, MD

Endocrinology, Diabetes & Metabolism · Jackson, MSNPI 1932132495

Payments from drug & device makers

$903,720in general payments, 2019–2025

Across 1,956 payments — averaging $462.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Corcept Therapeutics$367K
Amgen$164K
Novartis$136K
Boehringer Ingelheim$133K
Lilly USA, LLC$89K
Biomarin Pharmaceutical Inc.$2K
plus $14K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Corcept Therapeutics	381	$366,613
Amgen(2 entities)	328	$163,541
Novartis	30	$135,749
Boehringer Ingelheim	228	$132,783
Lilly USA, LLC	277	$88,864
Biomarin Pharmaceutical Inc.	1	$2,457
Novo Nordisk	137	$2,266
AbbVie	74	$1,418
Abbott	81	$1,383
AstraZeneca(2 entities)	65	$1,304
Sanofi-aventis U.S. LLC	30	$541
Medtronic(2 entities)	24	$505
Dexcom, Inc.	26	$481
Amneal Pharmaceuticals LLC	31	$423
Insulet Corporation	15	$394
Regeneron Healthcare Solutions, Inc.	18	$389
Bayer	19	$352
Amarin Pharma, Inc.	8	$348
Esperion Therapeutics, Inc.	15	$286
Tandem Diabetes Care, Inc.	15	$278
Merck	15	$236
Radius Health, Inc.	9	$225
Recordati_rare_diseases_inc.	11	$219
Pfizer	12	$219
GRT US Holding, Inc.	8	$203
Averitas Pharma Inc.	12	$180
Regeneron	2	$164
Ascendis Pharma Endocrinology Inc	5	$154
Axsome Therapeutics, Inc.	3	$152
Xeris Pharmaceuticals, Inc.	5	$152
Rhythm Pharmaceuticals, Inc.	3	$125
Chiesi USA, Inc.	2	$107
Neurocrine Biosciences, Inc.	5	$106
Johnson & Johnson	5	$105
Acella Pharmaceuticals, LLC	4	$75
Kowa Pharmaceuticals America, Inc.	4	$71
Tolmar, Inc.	4	$64
Ionis Pharmaceuticals, Inc.	3	$62
IBSA Pharma Inc.	3	$57
Ultragenyx Pharmaceutical Inc.	3	$55
RGH Enterprises LLC	1	$49
Currax Pharmaceuticals LLC	3	$48
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	3	$47
Lifescan, Inc.	3	$46
Shire North American Group Inc	3	$44
EUSA Pharma (US) LLC	2	$43
Amryt Pharma Holdings Ltd	2	$43
Sequel Med Tech, LLC	2	$39
Ascensia Diabetes Care US Inc.	2	$33
BETA Bionics, Inc.	2	$31
Nalpropion Pharmaceuticals LLC	2	$27
Aegerion Pharmaceuticals, Inc.	2	$27
Stryker	1	$24
Embecta Corp.	1	$23
Valeritas, Inc.	1	$19
Travere Therapeutics, Inc.	1	$17
BD	1	$17
Antares Pharma, Inc.	1	$15
Senseonics, Incorporated	1	$14
Acerus Pharmaceuticals Corporation	1	$13

How this compares

$903,720 in reported general payments places this provider in the 95th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.

See all endocrinology, diabetes & metabolism providers in Mississippi →

Medicare billing

Part B allowed, 2024

$379,229

Medicare patients

543

Services billed

13,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Jackson

Eric DyessJackson$885K
Ben SealeJackson$623K
Amanda SchieferJackson$204K
John SistrunkJackson$133K
Vishnu GarlaJackson$88K
Raymond GrenfellJackson$16K
Vanessa SandiferJackson$14K
John KnightJackson$9K
Jana PhillipsJackson$8K
Robert EvansJackson$8K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →